A detailed history of Sei Investments CO transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Sei Investments CO holds 26,805 shares of LGND stock, worth $3.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,805
Previous 48,065 44.23%
Holding current value
$3.05 Million
Previous $4.05 Million 33.69%
% of portfolio
0.0%
Previous 0.01%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$82.7 - $110.11 $1.76 Million - $2.34 Million
-21,260 Reduced 44.23%
26,805 $2.69 Million
Q2 2024

Aug 13, 2024

BUY
$68.53 - $87.91 $837,710 - $1.07 Million
12,224 Added 34.11%
48,065 $4.05 Million
Q1 2024

May 07, 2024

BUY
$68.64 - $89.2 $1.7 Million - $2.21 Million
24,784 Added 224.15%
35,841 $2.62 Million
Q4 2023

Feb 14, 2024

BUY
$49.57 - $72.63 $179,393 - $262,847
3,619 Added 48.66%
11,057 $789,000
Q3 2023

Nov 14, 2023

BUY
$58.86 - $72.67 $13,537 - $16,714
230 Added 3.19%
7,438 $445,000
Q2 2023

Aug 11, 2023

BUY
$69.53 - $79.33 $122,233 - $139,462
1,758 Added 32.26%
7,208 $519,000
Q1 2023

May 12, 2023

BUY
$65.67 - $77.08 $39,599 - $46,479
603 Added 12.44%
5,450 $400,000
Q4 2022

Feb 10, 2023

SELL
$61.72 - $96.74 $3,518 - $5,514
-57 Reduced 1.16%
4,847 $323,000
Q3 2022

Nov 14, 2022

BUY
$0.01 - $107.56 $21 - $228,134
2,121 Added 76.21%
4,904 $422,000
Q2 2022

Aug 15, 2022

BUY
$74.52 - $117.06 $12,444 - $19,549
167 Added 6.38%
2,783 $251,000
Q1 2022

May 13, 2022

SELL
$94.99 - $151.56 $1.01 Million - $1.61 Million
-10,639 Reduced 80.26%
2,616 $296,000
Q4 2021

Feb 14, 2022

SELL
$127.69 - $165.85 $259,593 - $337,173
-2,033 Reduced 13.3%
13,255 $2.04 Million
Q3 2021

Nov 12, 2021

BUY
$102.33 - $144.73 $1.06 Million - $1.5 Million
10,391 Added 212.19%
15,288 $2.13 Million
Q2 2021

Aug 06, 2021

SELL
$113.03 - $155.64 $155,416 - $214,004
-1,375 Reduced 21.92%
4,897 $640,000
Q1 2021

May 12, 2021

SELL
$99.52 - $215.83 $5.19 Million - $11.3 Million
-52,170 Reduced 89.27%
6,272 $863,000
Q4 2020

Feb 08, 2021

SELL
$80.55 - $106.05 $53,968 - $71,053
-670 Reduced 1.13%
58,442 $5.81 Million
Q3 2020

Dec 04, 2020

SELL
$89.56 - $126.72 $96,277 - $136,224
-1,075 Reduced 1.79%
59,112 $5.63 Million
Q3 2020

Nov 06, 2020

BUY
$89.56 - $126.72 $1.24 Million - $1.76 Million
13,896 Added 30.02%
60,187 $5.74 Million
Q2 2020

Aug 17, 2020

BUY
$68.28 - $123.65 $1.48 Million - $2.68 Million
21,638 Added 87.77%
46,291 $5.18 Million
Q2 2020

Aug 11, 2020

SELL
$68.28 - $123.65 $919,321 - $1.66 Million
-13,464 Reduced 35.32%
24,653 $2.59 Million
Q1 2020

May 14, 2020

BUY
$63.37 - $107.88 $839,525 - $1.43 Million
13,248 Added 53.27%
38,117 $2.76 Million
Q4 2019

Feb 06, 2020

SELL
$96.94 - $113.59 $5.21 Million - $6.11 Million
-53,783 Reduced 68.38%
24,869 $2.65 Million
Q3 2019

Nov 12, 2019

BUY
$86.25 - $120.16 $4.62 Million - $6.43 Million
53,514 Added 212.88%
78,652 $7.87 Million
Q2 2019

Aug 14, 2019

BUY
$107.38 - $129.34 $409,762 - $493,561
3,816 Added 17.9%
25,138 $2.9 Million
Q1 2019

May 15, 2019

SELL
$105.93 - $142.47 $699,243 - $940,444
-6,601 Reduced 23.64%
21,322 $2.72 Million
Q4 2018

Feb 13, 2019

BUY
$128.36 - $272.13 $1.18 Million - $2.5 Million
9,199 Added 49.13%
27,923 $6.24 Million
Q3 2018

Nov 08, 2018

SELL
$211.18 - $274.49 $1.34 Million - $1.74 Million
-6,337 Reduced 25.29%
18,724 $5.13 Million
Q2 2018

Aug 03, 2018

BUY
$150.77 - $207.98 $1.72 Million - $2.37 Million
11,395 Added 83.38%
25,061 $5.19 Million
Q1 2018

May 11, 2018

BUY
$138.63 - $182.62 $389,411 - $512,979
2,809 Added 25.87%
13,666 $2.26 Million
Q4 2017

Feb 08, 2018

BUY
$128.36 - $147.04 $69,442 - $79,548
541 Added 5.24%
10,857 $1.49 Million
Q3 2017

Nov 06, 2017

BUY
$120.91 - $137.94 $1.25 Million - $1.42 Million
10,316
10,316 $1.41 Million

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.92B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Sei Investments CO Portfolio

Follow Sei Investments CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.